Take ½ teaspoon of THIS before bed. Check your vision in 28 days.‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎



<[link removed]>

September 18


 



A retired surgeon says the fix for blurry vision is already in your kitchen

Find Out More →
<[link removed]>

 






Go to your kitchen pantry.

Find this one specific ingredient.

Take half a teaspoon.

<[link removed]>
Johns Hopkins confirmed it reopens the collapsed blood vessels starving your
retinal cells — the real reason your vision keeps getting worse.

No injections. No surgery. No prescriptions.

71,293 people already used this to get sharp 20/20 vision back.



See the exact pantry ingredient and the 7-second method for restoring your
vision
<[link removed]>

To your health!
 





CONNOR'S HEALTH NOTES
The Retina Sits Behind Two Barriers
Connor Hill · InsightfulWord · September 17, 2026
Nothing here is a reason to start or stop any treatment, supplement or
prescribed medication. Those decisions belong with a clinician who knows the
case. What follows concerns how substances reach the back of the eye, which is
a question of anatomy and pharmacology and has well-documented answers.

The retina is among the most thoroughly defended tissues in the body. It sits
behind two separate barriers, each formed by a continuous sheet of cells joined
by tight junctions, and their combined effect is that most of what circulates
in the blood never reaches the photoreceptors at all.

The inner barrier is formed by the endothelial cells lining the retinal blood
vessels. Unlike vessels elsewhere, these have no gaps between cells and no
windows through them, and they are supported by pericytes and by specialized
glial cells that maintain the arrangement. The structure is closely analogous
to the barrier protecting the brain.

The outer barrier is formed by the retinal pigment epithelium, a single layer
of cells sitting between the retina and the vascular bed that supplies it from
behind. These cells are likewise sealed to one another, and everything moving
from that blood supply into the retina passes through them rather than between
them.

The consequence is a size limit and a selectivity rule. Retinal vessels are
described in the reference literature as impermeable to molecules above roughly
twenty to thirty thousand daltons. What does cross is either small and
lipid-soluble enough to pass through membranes, or carried by a specific
transporter built for it — glucose by one, particular amino acids by others.

Everything else is excluded, and a family of efflux pumps in both barriers
actively returns a range of molecules to the blood after they have entered,
which is a further filter operating on precisely the compounds most likely to
arrive by accident.

This is why delivering medicine to the retina is one of the harder problems in
pharmacology, and why the treatments that do reach it are given by injection
into the eye rather than swallowed.

What follows is the two barriers and what forms them, why an oral dose is not
a delivered dose, how the drugs that do reach the retina get there, what has
actually been measured in the eye, and what a delivery claim would have to show.


The Two Barriers and What Forms Them

The architecture is worth holding precisely, because the two barriers guard
different approaches and fail in different diseases.

The retina has two blood supplies. The central retinal artery feeds the inner
layers through vessels running within the retina itself. The choroid, a dense
vascular bed behind the retina, supplies the outer layers including the
photoreceptors.

The inner barrier guards the first. Its endothelial cells are joined by tight
junctions, lack the fenestrations that make most capillaries leaky, and rest on
a continuous basement membrane with pericytes wrapped around them.

The outer barrier guards the second. The choroidal vessels are in fact quite
leaky, which would matter enormously were it not for the pigment epithelium
sitting between them and the retina, sealed cell to cell.

Both barriers are maintained actively rather than passively. The supporting
glial cells signal to the endothelium to keep the junctions tight, which is why
disruption of those cells appears early in several retinal diseases.

That last point is the clinically important one. Barrier breakdown is a
feature of disease rather than a route to treatment: when the barrier leaks,
fluid enters the retina where it does not belong, and the resulting swelling is
itself a major cause of vision loss.

Why an Oral Dose Is Not a Delivered Dose

The distance between swallowing something and it arriving at a tissue involves
several stages, each of which removes most of what started.

🩺 Clinical Signal 20,000 to 30,000 daltons The molecular size above which
retinal vessels are described as impermeable in the reference literature. The
retina is protected by two barriers: an inner one formed by tight junctions
between retinal vascular endothelial cells, and an outer one formed by tight
junctions between retinal pigment epithelial cells. Small essential molecules
such as glucose and specific amino acids cross by dedicated transporters; most
other substances do not cross at all. Source: reference literature on the
blood-retina barrier.

Support or oppose: should oral supplements be required to state whether the
active compound has been measured in the target tissue?

Supporters argue that a product claiming an effect on a specific organ is
making a delivery claim, that measuring tissue concentration is a standard
pharmacology experiment, and that consumers cannot distinguish a compound that
reaches its target from one that does not. Opponents answer that tissue
sampling in living people is impractical for most organs and impossible for
some, that requiring it would remove products with genuine systemic effects on
no evidence of harm, and that the appropriate standard is an outcome trial
rather than a concentration measurement. Which is better?

Hit reply — one line is enough.

Absorption is the first stage. A compound must survive the stomach, dissolve,
and cross the intestinal wall. Many plant compounds are poorly soluble and
poorly absorbed, and a large fraction of a swallowed dose never enters the
bloodstream at all.

First-pass metabolism is the second. Blood from the intestine goes to the
liver before it goes anywhere else, and the liver chemically modifies foreign
compounds efficiently. Many are converted to water-soluble forms and excreted,
which is the liver doing exactly its job.

Distribution is the third. Whatever survives is diluted into the whole
circulating volume and distributed across every tissue according to blood flow
and affinity. The eye is small and receives a correspondingly small share.

The barrier is the fourth and, for the retina, the decisive one. A compound
that has survived the first three stages still has to cross a sealed cell
layer, and the great majority do not.

Each stage multiplies. A compound with modest absorption, substantial
first-pass loss, wide distribution and no barrier transport can arrive at the
retina at a concentration many orders of magnitude below what produced an
effect in a laboratory dish.

That gap between the dish and the tissue is the single most common unstated
assumption in claims of this kind.

How Drugs That Do Reach the Retina Get There

The treatments that work on retinal disease illustrate the problem by the
lengths they go to.


Context — the changes that need attention rather than a pantry

Vision that drops suddenly in one eye, a dark curtain or shadow moving across
part of the field, a new shower of floaters or flashing lights, straight lines
that appear bent or wavy, or eye pain with redness and haloes around lights —
none of these are questions about diet. Several are emergencies in which the
delay before treatment determines how much sight is kept, and they warrant
same-day attention rather than an appointment in due course. Anyone noticing a
change in vision should have it examined rather than treated at home.

The principal treatments for the leading causes of central vision loss are
large protein molecules, far above the size that crosses either barrier, and
they are administered by injection directly into the vitreous cavity of the eye.

That route exists precisely because no other reliably works. It places the
drug inside the barrier rather than asking it to cross, and it is repeated at
intervals because the drug clears.

Implants releasing medication slowly inside the eye follow the same logic. So
do the surgical and laser approaches, which act on the tissue directly.

Where systemic administration is used in eye disease, it is generally for
conditions of the ocular surface, the orbit or inflammation involving
structures outside the barrier, or for infections where very high blood
concentrations are achievable.

Research into systemic delivery to the retina is active and is framed, in the
literature itself, as an effort to overcome the barrier — by targeting the
transporters that do exist, by temporarily modulating the junctions, or by
designing molecules that exploit a known carrier. That framing is the clearest
statement available that the default is exclusion.

What Has Actually Been Measured in the Eye

The empirical question — what concentration of a given compound appears in
retinal tissue after an oral dose — has an established experimental answer for
a small number of substances and no answer at all for most.

The measurement requires tissue, which in humans means eyes obtained after
death or during surgery, and this is why the human data is sparse and the
animal data is more extensive.

The clearest human evidence concerns the carotenoids concentrated in the
central retina. These are taken up selectively by specific binding proteins,
accumulate measurably in the macula, and their density can be measured
non-invasively. Supplementation raises that measured density, which is a
genuine demonstration of delivery to the tissue.

That case is instructive precisely because it is unusual. It works because a
dedicated transport and binding system exists for those molecules, and the
existence of that system is the exception rather than the rule.

For most compounds proposed as retinal remedies, no comparable measurement has
been published. That absence is not proof of failure, and it is the specific
evidence that would be required, and its absence should be noticed rather than
filled in.

The general principle is that a demonstration of effect in cultured cells
establishes that a compound can act on those cells at the concentration used,
and says nothing about whether that concentration is achievable in a living
retina by any route.

What a Delivery Claim Would Have to Show

The questions that resolve a claim in this area are few, and they can be asked
without any specialist knowledge.

The first is whether the compound was shown to reach the tissue, at what
concentration, and by what measurement.

The second is whether the concentration reached corresponds to the
concentration that produced the effect in whatever experiment is being cited. A
dish experiment states its concentration, and comparing the two numbers is
arithmetic.

The third is what the outcome measure was. A change in a laboratory marker is
not a change in vision, and vision measured under different conditions before
and after is not a comparison.

The fourth is whether there was a control group. Vision fluctuates, chart
performance improves with familiarity, and several retinal conditions have a
natural history that includes spontaneous improvement.

The fifth is whether the institution named in a claim published anything.
Research institutions maintain public listings of their publications, and an
attribution that cannot be traced to a paper is an attribution to a name rather
than to a finding.

The composite point is that the retina is behind two sealed cell layers that
exclude most of what circulates, that the treatments which work are injected
past them, and that a claim of oral delivery to this particular tissue is a
strong claim requiring the specific evidence that measurement in the eye
provides.


The bill, not the debate

The retina is protected by two barriers of tight-junctioned cells that exclude
molecules above roughly twenty to thirty thousand daltons and pump many smaller
ones back out. That is why the drugs that treat retinal disease are injected
into the eye rather than swallowed. When something taken by mouth is described
as acting on the retina, has the concentration in the tissue ever been measured?

Connor Hill reads every reply.

Sources checked • ScienceDirect Topics — blood-retina barrier, structure and
permeability —
[link removed]
<[link removed]> •
PubMed — inner blood-retinal barrier transporters and their role in retinal
drug delivery —[link removed]
<[link removed]> • PubMed — barrier modulation in
drug delivery to the retina —[link removed]
<[link removed]> • Proceedings of the National
Academy of Sciences — an experimental platform for systemic drug delivery to
the retina —[link removed]
<[link removed]> • National Eye
Institute — macular degeneration, diagnosis and treatment —
[link removed]

<[link removed]>
• National Eye Institute — diabetic retinopathy and macular edema —
[link removed]

<[link removed]>
Connor Hill · InsightfulWord



You’re receiving this email from Insightful Word (IW), a brand of TerraTrance
Technologies, LLC.

Our mailing address: 200 Broadway Blvd NEAlbuquerque, NM 87102



Have a question or need assistance? Reply directly to this email or contact us
[email protected] <mailto:[email protected]>



The content of this email may not be copied, reproduced, forwarded, shared, or
distributed without the prior written consent of TerraTrance Technologies, LLC.

Privacy Policy <[link removed]>
Terms & Conditions <[link removed]>
Unsubscribe
<[link removed]>



© 2026 Insightful Word (IW). All Rights Reserved.